Biotechnology
By advising some of the fastest growing biotechs, we move as fast as our clients' needs - staying ahead of the trends.
Whilst the financial markets are proving more receptive to biotechs than in the past few years, access to capital is still limited, emphasising the need for a strong business case and development pipeline. Consolidation is seen as one solution, however, there is also a noticeable increase in early stage licensing deals to secure much needed funding for the sector.
Alizyme
Advised on their £32.8m fundraising - the largest secondary fundraising in the sector 2005.
Genmab
Advised in relation to various US and European collaboration and licensing arrangements concerning transgenic mice and fully human antibodies.
TopoTarget
Advised this Danish biotechnology company on the acquisition of G2M Cancer Drugs AG, the German biotech, and on English law issues relating to TopoTarget’s Danish IPO.